Recommended

New webinar in 2025: Trends for life sciences quality leaders in 2025 – mastering what matters! Register your details now to secure your place!
Discover how a well-orchestrated digital ecosystem drives laboratory efficiency and innovations in this compelling webinar. Register now!
New upcoming webinar: Navigating pharmaceutical environmental monitoring in a changing industry! Register your details today!
Explore our new Pharma Horizons: Sustainability report for key developments in the pharmaceutical industry!

List view / Grid view

Mass Spectrometry

 

Mass Spectrometry In-Depth Focus 2014
Mass Spectrometry In-Depth Focus 2014
article

Mass Spectrometry: In-Depth Focus 2014

15 April 2014 | By

In this free-to-view Mass Spectrometry In-Depth Focus: Some tricks and tools for structural characterisation of natural products using Electrospray mass spectrometry, Mass spectrometry in the biopharmaceutical industry: from the mundane to the cutting edge, and Mass Spectrometry roundtable...

Mass spectrometry
Mass spectrometry
article

Practical considerations in analysing biologically active peptides by Electrospray Ionisation (ESI) Mass Spectrometry

22 October 2013 | By Birthe V. Nielsen, Faculty of Engineering and Science, University of Greenwich

Neuromodulators such as calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) act as biomarkers for pain assessment (pre-clinical). These markers can be detected at low concentrations by Electrospray Ionisation (ESI) Mass Spectrometry (MS). Currently, little is known about the factors affecting responsiveness in the ESI process though the response…

Label-free quantitative proteomics: Why has it taken so long to become a mainstream approach?
Label-free quantitative proteomics: Why has it taken so long to become a mainstream approach?
article

Label-free quantitative proteomics: Why has it taken so long to become a mainstream approach?

13 June 2013 | By Thierry Le Bihan, SynthSys and Institute of Structural and Molecular Biology, University of Edinburgh

In recent years, mass spectrometry (MS) based proteomics has moved from being a qualitative tool (used to mainly identify proteins) to a more reliable analysis tool, allowing relative quantitation as well as absolute quantitation of a large number of proteins. However, the developed quantitative methods are either specific for certain…

Cancer Research UK drug launched in its first clinical trial
Cancer Research UK drug launched in its first clinical trial
article

Future trends in drug discovery technology

18 December 2012 | By Terry McCann, TJM Consultancy

The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion1. Herper1 observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of…

Figure 1: Sample preparation techniques for mass spectrometry based pharmaceutical and metabolite analysis. The three approaches discussed in the paper are outlined: (Top) mass spectrometry imaging from dosed tissue sections, (Middle) liquid chromatography mass spectrometry of tissue extracts or plasma/serum samples, (Bottom) gas chromatography mass spectrometry of plasma/serum samples
Figure 1: Sample preparation techniques for mass spectrometry based pharmaceutical and metabolite analysis. The three approaches discussed in the paper are outlined: (Top) mass spectrometry imaging from dosed tissue sections, (Middle) liquid chromatography mass spectrometry of tissue extracts or plasma/serum samples, (Bottom) gas chromatography mass spectrometry of plasma/serum samples
article

MS-based methods for detection, quantitation and localisation of pharmaceuticals and metabolites in biological samples

18 December 2012 | By Tyler Greer, Department of Chemistry, University of Wisconsin-Madison and Lingjun Li, Department of Chemistry & School of Pharmacy, University of Wisconsin-Madison

Mass spectrometry is a powerful, multi-faceted technique capable of analysing pharmaceuticals and their metabolites in biological matrices. Although it is more commonly applied to proteins, peptides and lipids, an increasing number of studies use mass spectrometry based techniques to detect, quantitate and localise pharmaceuticals and their metabolites. The availability of…

article

Recent developments in the use of LCMS in process pharmaceutical chemistry

28 February 2012 | By Dr. Florence O. McCarthy, Department of Chemistry, Analytical and Biological Chemistry Research Facility, University College Cork

Liquid Chromatography Mass Spectrometry (LCMS) is a powerful technique that has recently undergone exponential growth in its application to pharmaceutical synthesis. This perspective will outline the general principles of LCMS, detail some recent approaches and the benefits to be derived from its use at an early stage of process development.…

FIGURE 1 Schematic overview of the MALDI-MSI process as applied to imaging compound and metabolite distributions in a whole body rat sample. From one section of an animal dosed with the unlabelled compound, the substance and metabolite distributions can be acquired
FIGURE 1 Schematic overview of the MALDI-MSI process as applied to imaging compound and metabolite distributions in a whole body rat sample. From one section of an animal dosed with the unlabelled compound, the substance and metabolite distributions can be acquired
article

MALDI-mass spectrometry imaging applied to drug discovery and development

19 October 2011 | By Brendan Prideaux, Dieter Staab, Gregory Morandi, Nicole Ehrhard and Markus Stoeckli, Novartis Institutes for BioMedical Research

Since its introduction in the field of biomedical imaging over 10 years ago1, matrixassisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) has played an ever increasing role in drug discovery and development and is now utilised in laboratories of many leading pharmaceutical companies and collaborating academic institutions.

Detection of microorganisms using cellular component-based rapid method technologies
Detection of microorganisms using cellular component-based rapid method technologies
article

Detection of microorganisms using optical spectroscopic-based rapid method technologies

31 August 2011 | By Michael J. Miller, President, Microbiology Consultants, LLC

This is the fourth in a series of articles on rapid microbiological methods that will appear in European Pharmaceutical Review during 2011. Previously, we discussed a number of cellular-component rapid microbiological methods (RMMs), such as ATP bioluminescence, fatty acid analysis, MALDI and SELDI time of flight mass spectrometry, Fourier transform-infrared…

Figure 1 (A) the increase in mass resolving power of commercially available instruments from 1996 to the present and (B) the improvement in mass accuracy over the same time period
Figure 1 (A) the increase in mass resolving power of commercially available instruments from 1996 to the present and (B) the improvement in mass accuracy over the same time period
article

Evolution and revolution in time-of-flight mass spectrometry and its impact on research within the pharmaceutical industry

20 June 2011 | By

Time of flight mass spectrometry (TOF-MS) has been an attractive choice of instrument for many years due to its potentially unlimited m/z range, high-speed acquisition, accurate mass measurement capability and sensitivity. Originally commercialised in the late 1950’s by the Bendix Corporation1, several physical and technical issues of the early TOF…